A review of topiramate and phentermine: a combined therapeutic approach for obesity

Reference

• Olshanksy SJ, Passaro DJ, Hershow RC etal. A potential decline in life expectancy in the United States in the 21st century. N.Engl.J.Med. 352(11), 1138–1145 (2005).
   Google Scholar
• Pischon T, Boeing H, Hoffmann K etal. General and abdominal adiposity and risk of death in Europe. N.Engl.J.Med. 359(20), 2105–2120 (2008).
   Google Scholar
• Fontaine KR, Tedden DT, Wang C, Westfall AO, Allison DB. Years of life lost due to obesity. JAMA 289(2), 187–193 (2003).
   Google Scholar
• Haslam DW, James WPT. Obesity. Lancet 366(9492), 1197–1209 (2005). ▪ Good overall global review of obesity.
   Google Scholar
• Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world – a growing challenge. N.Engl.J.Med. 356(3), 213–215 (2007).
   Google Scholar
• Wadden TA, West DS, Neiberg RH etal. Look AHEAD Research Group: one-year weight losses in the look AHEAD study: factors associated with success. Obesity17(4), 713–722 (2009).
   Google Scholar
• Gadde KM, Allison DB. Combination therapy for obesity and metabolic disease. Curr.Opin.Endocrinol.Diabet.Obes. 16(5), 353–358 (2009).
   Google Scholar
• Avena NM, Rada P, Hoebel BG. Evidence for sugar addiction: behavioral and neurochemical effects of intermittent, excessive sugar intake. Neurosci.Biobehav.Rev. 32(1), 20–39 (2008).
   Google Scholar
• Halford JC, Boyland EF, Blundell JE, Kirkham TC, Harrold JA. Pharmacological management of appetite expression in obesity. Nat.Rev. 6, 255–269 (2010).
   Google Scholar
• Dayyeh BK, Kaplan LM. Medical therapy for obesity. Gastrointest.Endosc.Clin.N.Am. 21, 203–212 (2011).
   Google Scholar
• Salem V, Bloom SR. Approaches to the pharmacological treatment of obesity. Exp. Rev.Clin.Pharmacol.3(1), 73–88 (2010). ▪ Good review of pharmacologic approaches to obesity.
   Google Scholar
• Rucker D, Padwal R, Ki SK, Curioni C, Lau DCW. Long term pharmacotherapy for obesity and overweight: updated meta-ana lysis. BMJ 335(7631), 1194–1199 (2007).
   Google Scholar
• James WP, Caterson ID, Coutinho W etal. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N.Engl.J.Med. 363(10), 905–917 (2010).
   Google Scholar
• Rothman RB, Baumann MH. Appetite suppressants, cardiac valve disease and combination pharmacotherapy. Am.J.Ther. 16(4), 354–364 (2009).
   Google Scholar
• Witkamp RF. Current and future drug targets in weight management. Pharm.Res. 28(8), 1792–1818 (2011). ▪ Extensive review of drug targets for obesity.
   Google Scholar
• Ioannides-Demos LL, Piccenna L, McNeil JJ. Pharmacotherapies for obesity: past, current, and future therapies. J.Obes. doi: 10.1155/2011/179674 (2011) (Epub ahead of print).
   Google Scholar
• Field BC, Chaudhri OB, Bloom SR. Obesity treatment: novel peripheral targets. Br. J.Clin.Pharmacol. 68(6), 830–843 (2009).
   Google Scholar
• Nelson DL, Gehlert DR. Central nervous system biogenic amine targets for control of appetite and energy expenditure. Endocrine 29(1), 49–60 (2006).
   Google Scholar
• Verrotti A, Scaparrotta A, Agostinelli S, DiPillo S, Chiarelli F, Grosso S. Topiramate-induced weight loss: a review. EpilepsyRes. 95(3), 189–199(2011). ▪ Excellent review of topiramate mechanisms and weight loss.
   Google Scholar
• Schutt M, Brinkoff J, Drenckhan M, Lehnert H, Sommer C. Weight reducing and metabolic effects of topiramate in patients with migraine – an observational study. Exp. Clin.Endocrinol.Diabet. 118, 449–452 (2010).
   Google Scholar
• Kramer CK, Leitao CB, Pinto LC, Canani LH, Azevedo MJ, Gross JL. Efficacy and safety of topiramate on weight loss: a meta-ana lysis of randomized controlled trials. Obes.Rev. 12(5), E338–E347 (2011).
   Google Scholar
• Tremblay A, Chaput JP, Berube-Parent S etal. The effect of topiramate on energy balance in obese men: a 6 month double-blind randomized placebo-controlled study with a 6-month open-label extension. Eur.J.Clin. 63(2), 123–134 (2007).
   Google Scholar
• Gadde KM, Allison DB, Ryan DH etal. Effects of low-dose, controlled-release, phentermine plus topriamate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, Phase 3 trial. Lancet 377(9774), 1341–1352 (2011).
   Google Scholar
• Hay PJ, Claudino AM. Clinical psychopharmacology of eating disorders: a research update. Int.J.Neuropsychopharm. doi: 10.1017/S1461145711000460 (2011) (Epub ahead of print).
   Google Scholar
• Leombrini P, Lavagnino L, Fassino S. Treatment of obese patients with binge eating disorder using topiramate: a review. Neuropsychiatr.Dis.Treat. 5, 385–392 (2009).
   Google Scholar
• Bialer M, Doose DR, Murthy B etal. Pharmacokinetic interactions of topiramate. Clin.Pharmacokinet. 43(12), 763–780 (2004).
   Google Scholar
• Brownell KD. TheLEARNProgramfor WeightManagement. The Life Style Company, TX, USA (2000).
   Google Scholar
• Allison DB, Gadde KM, Garvey WT etal. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity doi:10.1038/ oby.2011.330 (2011) (Epub ahead of print).
   Google Scholar
• Garvey WT, Ryan DH, Look M etal. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/ topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, Phase 3 extension study. Am.J.Clin.Nutr. doi:10.3845/ ajcn.111.024927 (2011) (Epub ahead of print).
   Google Scholar
• Hunt S, Russell WH, Smithson L etal. Topiramate in pregnancy: preliminary experience from the UK epilepsy and pregnancy register. Neurology 71(4), 272–276 (2008).
   Google Scholar
• Hernandez-Diaz S, Mittendorf R, Homes LB. Comparative safety of topiramate during pregnancy. BirthDefectsRes.(PartA) 88, 408 (2010).
   Google Scholar
• Molgaard-Nielsen D, Hviid A. Newergeneration antiepileptic drugs and the risk of major birth defects. JAMA 305(19), 1996–2002 (2011).
   Google Scholar
• Pack A, Meador K, Bhattachuria A. Retrospective analysis of major congenital malformations (MCMs) and oral clefts (OC) associated with inutero topiramate exposure. Epilepsia 52(6), 262 (2011).
   Google Scholar
• Hendricks EJ, Greenway FL, Westman EC, Gupta AK. Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacology for obesity. Obesity19, 2351-2360 (2011).
   Google Scholar